ABSTRACT
The accelerated global progress in the research and development of automobile products, and the use of new technologies, such as the Internet, cloud computing and big data, to coordinate development platforms in different regions and fields, can reduce the duration and cost of development and testing. Specifically, in the context of the current coronavirus disease (COVID-19) pandemic, which has caused great obstacles to normal logistics and transportation, personnel exchanges and information communication, platforms that can support global operation are significant for product testing and validation, because they eliminate the need for the transportation of personnel and equipment. Therefore, the establishment of a distributed test and validation platform for automotive powertrain systems, which can integrate software and hardware testing, is important in terms of both scientific research and industrialization. The main technical difficulties associated with such test and validation platforms include data transmission and the control of the transmission effect. A distributed test and validation platform for a fuel cell electric vehicle powertrain system is proposed herein. The two-time-scale Markov chain is used to simulate the delay between two places (China and Germany), and the least-squares support vector machine (LSSVM) method is used to optimize the transmission effect. The results show that the two-time-scale Markov chain model can effectively simulate the delay between two nations, and that its probability distribution is close to the measured value. The LSSVM method is effectively optimized for all four indicators (velocity, fuel cell output power, battery output power and electric motor output torque). This method can be effectively used in the remote development test validation of vehicle powertrain system. © 2021 SAE Technical Papers. All rights reserved.
ABSTRACT
COVID-19, caused by SARS-COV-2, has the characteristics of world epidemic, highly infectious and large base of death. In China, transmission route of SARS-COV-2 has been contained so effectively that COVID-19 has been well controlled due to the proactive national prevention and control strategy. However, not only does it bring a huge impact on the existing medical structure model, but also an objective impact on the treatment of patients with chronic diseases such as malignant tumors. Based on the progress reported in the domestic and international literatures and the actual management experience of our team, this paper reflects on the treatment strategies for patients with gastrointestinal stromal tumor (GIST) during the epidemic period of COVID-19. We focus on risk stratification for primary GIST and forming treatment strategies accordingly. Major considerations include the impact of delayed operation, the burden of medical resources, the waiting time for elective operation, and the principle of emergency operation. In addition, we focus on the level of evidence for non-surgical approaches with a view to developing a holistic strategy of "priority management principles" to guide clinical treatment in the context of limited resources and different GIST priorities.
Subject(s)
COVID-19 , Gastrointestinal Stromal Tumors , China , Humans , SARS-CoV-2ABSTRACT
In December 2019, a new outbreak of corona virus disease 2019 began to occur. Its pathogen is 2019-nCoV, which has the characteristics of strong infectivity and general susceptibility. The current situation of prevention and control of new coronavirus pneumonia is severe. In this context, as front-line medical workers bearing important responsibilities and pressure, while through strict management strategy, we can minimize the risk of infection exposure. By summarizing the research progress and guidelines in recent years in the fields of colorectal cancer disease screening, treatment strategies (including early colorectal cancer, locally advanced colorectal cancer, obstructive colorectal cancer, metastatic colorectal cancer and the treatment of patients after neoadjuvant therapy), the choice of medication and time limit for adjuvant therapy, the protective measures for patients undergoing emergency surgery, the re-examination of postoperative patients and the protection of medical staff, etc., authors improve treatment strategies in order to provide more choices for patients to obtain the best treatment under the severe epidemic situation of new coronavirus pneumonia. Meanwhile we hope that it can also provide more timely treatment modeling schemes for colleagues.